BAY 43-9006
Sponsors
National Cancer Institute (NCI), Jules Bordet Institute, British Columbia Cancer Agency, M.D. Anderson Cancer Center
Conditions
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the ProstateAdvanced Unresectable Gastric CancerFallopian Tube CancerHHV-8Head and Neck NeoplasmsKSHVKaposi's Sarcoma
Phase 1
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
CompletedNCT00095459
Start: 2004-11-02End: 2012-07-20Updated: 2019-12-17
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
TerminatedNCT00287495
Start: 2006-02-02End: 2017-10-18Updated: 2019-12-12
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
CompletedNCT00533585
Start: 2006-05-31End: 2016-01-31Updated: 2016-02-10
Phase 2
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
CompletedNCT00090545
Start: 2004-09-01End: 2009-04-01Updated: 2018-06-14
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
CompletedNCT00199160
Start: 2005-04-30End: 2010-06-30Updated: 2015-05-20
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
CompletedNCT00253370
Start: 2005-10-31End: 2010-09-30Updated: 2014-11-24
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
CompletedNCT00326495
Start: 2006-05-10End: 2014-11-07Updated: 2017-07-24
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
CompletedNCT00430235
Start: 2007-03-31Updated: 2010-08-05
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
CompletedNCT00436215
Start: 2006-12-12End: 2014-09-27Updated: 2020-11-23